The research-based pharmaceutical industry in Switzerland is right at the forefront of research and development in the field of rare diseases.  © Barbara Jung

The research-based pharmaceutical industry in Switzerland is right at the forefront of research and development in the field of rare diseases. 
© Barbara Jung

In May 2015, the Federal Council approved the plan to implement the national concept for combating rare diseases. The concept had been called for in a proposal put forward by National Councillor Ruth Humbel (CVP). As a member of IGSK (an interest group for combating rare diseases), Interpharma lends its backing to the implementation of the concept, which should be completed by 2017. While Interpharma supports the implementation in principle, key questions have yet to be settled, such as the funding of measures, the promotion of research and binding steps for equal rights in the reimbursement of costs for diagnoses and treatments.